Senekjian E K, Weiser P A, Talerman A, Herbst A L
Department of Obstetrics and Gynecology, University of Chicago, Pritzker School of Medicine, Illinois.
Cancer. 1989 Sep 15;64(6):1183-7. doi: 10.1002/1097-0142(19890915)64:6<1183::aid-cncr2820640603>3.0.co;2-n.
This report presents five adolescent girls and adult women with small cell carcinoma of the ovary (SCCO) who were treated with a polychemotherapy regimen consisting of vinblastine, cisplatin, cyclophosphamide, bleomycin, Adriamycin (doxorubicin), and etoposide (VPCBAE). Two patients had Stage IA, one Stage IIC, and two Stage IIIA disease. Initial therapy consisted of unilateral salpingo-oophorectomy in two cases and total abdominal hysterectomy and bilateral salpingo-oophorectomy in three cases. Three patients remained clinically free of disease after six courses of VPCBAE and the two patients who had measurable pelvic disease before the administration of chemotherapy had objective responses. Four patients died of disease from 11 to 18 months after initial laparotomy. One patient is alive and disease-free at 29 months. The VPCBAE combination appears to be effective in select cases of SCCO. A study of the efficacy of VPCBAE in a larger group of patients with SCCO seems to be indicated.
本报告介绍了5例接受长春花碱、顺铂、环磷酰胺、博来霉素、阿霉素（多柔比星）和依托泊苷（VPCBAE）联合化疗方案治疗的卵巢小细胞癌（SCCO）青春期女孩和成年女性。2例患者为ⅠA期，1例为ⅠC期，2例为ⅢA期。初始治疗包括2例行单侧输卵管卵巢切除术，3例行全腹子宫切除术及双侧输卵管卵巢切除术。3例患者在接受6个疗程的VPCBAE治疗后临床无疾病，2例在化疗前有可测量盆腔疾病的患者有客观反应。4例患者在初次剖腹手术后11至18个月死于疾病。1例患者在29个月时存活且无疾病。VPCBAE联合方案似乎对部分SCCO病例有效。似乎有必要对更大组的SCCO患者进行VPCBAE疗效研究。
